Importance of Artificial Intelligence to Improve Warehouse Processes at Óptica Pinar del Río
Keywords:
ALMACENES; PROCESOS; INTELIGENCIA ARTIFICIAL.; WAREHOUSES; PROCESSES; ARTIFICIAL INTELLIGENCE.; ARMAZÉNS; PROCESSOS; INTELIGÊNCIA ARTIFICIAL.Abstract
Introduction: the use of Artificial Intelligence (AI) in storage procedures is transforming the sector, opening the doors to a new era of smart warehouses. These innovations make it possible to achieve extraordinary levels of efficiency, accuracy, and optimization, resulting in dynamic, agile warehouses capable of quickly responding to future demands.
Objective: to determine the importance of AI in improving the processes carried out in the Optical and Auditory Warehouse of the Province of Pinar del Río.
Methods: a documentary review was conducted on AI applied to the Provincial Optical and Auditory Warehouse, with the aim of optimizing warehouse processes. This included bibliographic review articles and original research, as well as the methodology used. Articles of sufficient timeliness and scientific quality were selected.
Results: in general terms, the relevance of AI for the Provincial Optical and Auditory Warehouse of Pinar del Río Province is highlighted, paving the way toward a future full of changes and challenges. This objective is achieved through the automation of tasks and activities, as well as the reduction of manual processes.
Conclusions: the pressing need to implement new mechanisms in warehouses that turn them into smarter spaces powered by AI has been confirmed. These systems will have the capacity to optimize efficiency in order-picking routes, achieving this goal through task and activity automation, while minimizing manual processes.
Downloads
References
1. Cooke G, Watson C, Deckx L, Pirotta M, Smith J, van Driel ML. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev [Internet]. 2022 [citado 12/10/25]; 1(1):CD009151. Disponible en: https://doi.org/10.1002/14651858.cd009151.pub2
2. Jaqueti Aroca J, Ramiro Martínez P, Molina Esteban LM, Fernández González AM, García-Arata I, Prieto Menchero S. Epidemiología y etiología de la candidiasis vaginal en mujeres españolas e inmigrantes en Fuenlabrada (Madrid). Rev Esp Quimioter [Internet]. 2020 [citado 12/10/25]; 33(3):187-192. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7262383/
3. Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, Bohbot JM, et al. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Front Cell Infect Microbiol [Internet]. 2022 [citado 12/10/25]; 12:934353. Disponible en: https://doi.org/10.3389/fcimb.2022.934353
4. Ugalde González F, Rivera Gutierrez H, Durán Méndez MJ. Candidiasis vulvovaginal recurrente. Rev. Méd. Sinerg. [Internet]. 2021 [citado 12/10/25]; 6(9): e700. Disponible en: https://www.revistamedicasinergia.com/index.php/rms/article/view/700
5. Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, et al. Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy. Front Cell Infect Microbiol [Internet]. 2023 [citado 12/10/25]; 13:1123026. Disponible en: https://doi.org/10.3389/fcimb.2023.1123026
6. Xiao Z, Liang Y, Zhang X, Zhu Y, Huang L, Fan S. Three-Dose Antifungal Treatment Improves the Efficacy for Severe Vulvovaginal Candidiasis. Mycopathologia [Internet]. 2024 [citado 12/10/25]; 189(6):93. Disponible en: https://doi.org/10.1007/s11046-024-00889-4
7. Picheta N, Piekarz J, Burdan O, Satora M, Tarkowski R, Kułak K. Phytotherapy of Vulvovaginal Candidiasis: A Narrative Review. Int J Mol Sci [Internet]. 2024 [citado 12/10/25]; 25(7):3796. Disponible en: https://doi.org/10.3390/ijms25073796
8. Sobel JD, Nyirjesy P. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol [Internet]. 2021 [citado 12/10/25]; 16:1453-1461. Disponible en: https://doi.org/10.2217/fmb-2021-0173
9. Jaeger M, Pinelli M, Borghi M, Constantini C, Dindo M, van Emst L, et al. A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Sci Transl Med [Internet]. 2019 [citado 12/10/25]; 11(496): eaar3558. Disponible en: https://doi.org/10.1126/scitranslmed.aar3558
10. Sociedad Española de Ginecologia y Obstetricia. Diagnóstico y tratamiento de las infecciones vulvovaginales. Prog. obstet. Ginecol [Internet]. 2022 [citado 12/10/25]; 65(2): 61-75. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=8452285&orden=0&info=link
11. Jafarzadeh L, Ranjbar M, Nazari T, Naeimi Eshkaleti M, Aghaei Gharehbolagh S, Sobel JD, et al. Vulvovaginal candidiasis: An overview of mycological, clinical, and immunological aspects. J Obstet Gynaecol Res [Internet]. 2022 [citado 12/10/25]; 48(7):1546-1560. Disponible en: https://doi.org/10.1111/jog.15267
12. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis [Internet]. 2018 [citado 12/10/25]; 18(11):e339-e347. Disponible en: https://doi.org/10.1016/s1473-3099(18)30103-8
13. MacAlpine J, Lionakis MS. Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis. Cell Host Microbe [Internet]. 2024 [citado 12/10/25]; 32(10):1654-1667. Disponible en: https://doi.org/10.1016/j.chom.2024.08.018
14. Denison HJ, Worswick J, Bond CM, Grimshaw JM, Mayhew A, Gnani Ramadoss S, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev [Internet]. 2020 [citado 12/10/25]; 8(8):CD002845. Disponible en: https://doi.org/10.1002/14651858.cd002845.pub3
15. Phillips NA, Bachmann G, Haefner H, Martens M, Stockdale C. Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus. Womens Health Rep (New Rochelle) [Internet]. 2022 [citado 12/10/25]; 3(1):38-42. Disponible en: https://doi.org/10.1089/whr.2021.0065
16. Ordaya EE, Clement J, Vergidis P. The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective. Mycopathologia [Internet]. 2023 [citado 12/10/25]; 188(6):937-948. Disponible en: https://doi.org/10.1007/s11046-023-00759-5
17. Herreras Gómez LR, Cárdenas López V. Perfil de resistencia antifúngica en el tratamiento de candidiasis vaginal: Un diagnóstico de agentes etiológicos. Rev haban cienc méd [Internet]. 2022 [citado 12/10/25]; 21(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2022000200011&lng=es
18. Conte J, Parize AL, Caon T. Advanced Solid Formulations For Vulvovaginal Candidiasis. Pharm Res [Internet]. 2023 [citado 12/10/25]; 40(2):593-610. Disponible en: https://doi.org/10.1007/s11095-022-03441-5
19. Powell A, Ghanem KG, Rogers L, Zinalabedini A, Brotman RM, Zenilman J, et al. Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. Sex Transm Dis [Internet]. 2019 [citado 12/10/25]; 46(12):810-812. Disponible en: https://doi.org/10.1097/olq.0000000000001063
20. Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug Des Devel Ther [Internet]. 2023 [citado 12/10/25]; 17:363-367. Disponible en: https://doi.org/10.2147/dddt.s339349
21. Barnes KN, Yancey AM, Forinash AB. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis. Ann Pharmacother [Internet]. 2023 [citado 12/10/25]; 57(1):99-106. Disponible en: https://doi.org/10.1177/10600280221091301
22. Wang X, Chen L, Ruan H, Xiong Z, Wang W, Qiu J, et al. Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial. Antimicrob Agents Chemother [Internet]. 2024 [citado 12/10/25]; 68(1):e0077823. Disponible en: https://doi.org/10.1128/aac.00778-23
23. Lanier C, Melton TC. Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review. Ann Pharmacother [Internet]. 2024 [citado 12/10/25]; 58(6):636-644. Disponible en: https://doi.org/10.1177/10600280231195649
24. Li L, Zhang X, Li Q, Zhong W, Zou H. The Increasing Trend of Triazole-Resistant Candida from Vulvovaginal Candidiasis. Infect Drug Resist [Internet]. 2024 [citado 12/10/25]; 17:4301-4310. Disponible en: https://doi.org/10.2147/idr.s474304
25. Mittelstaedt R, Kretz A, Levine M, Handa VL, Ghanem KG, Sobel JD, et al. Data on Safety of Intravaginal Boric Acid Use in Pregnant and Nonpregnant Women: A Narrative Review. Sex Transm Dis [Internet]. 2021 [citado 12/10/25]; 48(12):e241-e247. Disponible en: https://doi.org/10.1097/olq.0000000000001562
26. Akinosoglou K, Schinas G, Polyzou E, Tsiakalos A, Donders GGG. Probiotics in the Management of Vulvovaginal Candidosis. J Clin Med [Internet]. 2024 [citado 12/10/25]; 13(17):5163. Disponible en: https://doi.org/10.3390/jcm13175163
27. Keikha N, Fouladi B, Yadegari MH. The efficacy and safety of current treatment of vulvovaginal candidiasis: An umbrella review of systematic reviews and meta-analyses. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2025 [citado 12/10/25]; 398(7):7713-7720. Disponible en: https://doi.org/10.1007/s00210-025-03852-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pedro Acosta Candelaria, Claudia Permuy Díaz, Yaicel García Benítez, Yusleivy Rivers Martínez, Mayenny Linares Río, Darianna Cruz Márquez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
